[A clinical trial of lansoprazole in the treatment of duodenal ulcer]

Zhonghua Nei Ke Za Zhi. 1995 Sep;34(9):606-8.
[Article in Chinese]

Abstract

To evaluate the efficacy of a second generation acid pump inhibitor-lansoprazole (L) a controlled clinical trial in 72 patients of duodenal ulcer was carried out with omeprazole (O) as control. The results showed that the ulcer healing rate after 4-week treatment was 97.4% in lansoprazole group and 91.2% in omeprazole, while the effective rate was 100% and 97.1% respectively (P > 0.05). Ulcer related pain was relieved more quickly in lansoprazole group. The pain relief rate after treatment of 3 days was different significantly between the two group, being 74.3% (L) and 51.6% (O) respectively (P < 0.05). No marked side-effect was observed in lansoprazole group. It is shown that lansoprazole is effective and safe for treatment of duodenal ulcer.

Publication types

  • Clinical Trial
  • Clinical Trial, Phase II
  • Comparative Study
  • English Abstract
  • Randomized Controlled Trial

MeSH terms

  • 2-Pyridinylmethylsulfinylbenzimidazoles
  • Adult
  • Aged
  • Anti-Ulcer Agents / therapeutic use*
  • Duodenal Ulcer / drug therapy*
  • Female
  • H(+)-K(+)-Exchanging ATPase / therapeutic use
  • Humans
  • Lansoprazole
  • Male
  • Middle Aged
  • Omeprazole / analogs & derivatives*
  • Omeprazole / therapeutic use
  • Proton Pump Inhibitors*

Substances

  • 2-Pyridinylmethylsulfinylbenzimidazoles
  • Anti-Ulcer Agents
  • Proton Pump Inhibitors
  • Lansoprazole
  • H(+)-K(+)-Exchanging ATPase
  • Omeprazole